# Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Canonical URL: https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-enters-into-clinical-trial-services-agreement-with-periness-ltd-to-accelerate-development-of-dnase-i-oncology-program
Ticker: XBIO
Company: Xenetic
Source: Xenetic
Published: 2024-12-05 13:45 EST
Original Source URL: https://ir.xeneticbio.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-04 12:40 EST — [Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-from-the-israeli-ministry-of-health-to-conduct-exploratory-investigator-initiated-study-of-dnase-i-in-combination-with-anti-cd19-car-t-cells-in-large-b-cell-lymphoma) — Source: Xenetic
- 2026-06-01 13:02 EST — [Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-showcases-compelling-asco-2026-data-demonstrating-dnase-i-significantly-enhances-car-t-cell-persistence-tumor-control-and-survival) — Source: Xenetic
- 2026-05-13 12:05 EST — [Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-reports-first-quarter-2026-financial-results-and-highlights-continued-advancement-of-dnase-oncology-platform) — Source: Xenetic
- 2026-04-22 13:00 EST — [Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-2026-asco-annual-meeting) — Source: Xenetic
- 2026-03-13 12:00 EST — [Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-reports-full-year-2025-financial-results) — Source: Xenetic
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)